Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin

• US 20080213385A1
• Filed: 08/08/2006
• Published: 09/04/2008
• Est. Priority Date: 08/10/2005
• Status: Abandoned Application

• Current Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SPA (Alfasigma S.p.A.)
• Original Assignee: Sigma-Tau Industrie Farmaceutiche Riunite SPA (Alfasigma S.p.A.)
• Inventors: Kalb, Oskar, Wirth, Wolfgang, Ottinger, Isabel, Stebler, Walter, Taillardat, Agnes
• Application Number:
  US11/996,638
• Publication Number:
  US 20080213385A1
• Time in Patent Office: Days
• US Class Current: 424/499
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis

Abstract

The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer.

Claims

1. A composition comprising:

(a) nanoparticles of 7-t-butoxyiminomethylcamptothecin;

(b) at least one surface stabilizer, wherein the nanoparticles have an effective average particle size of less than about 4,000 nm; and

(c) showing at least a 1.5-fold better bioavailability than the unformulated drug in a subject.

2. The composition of claim 1, wherein the 7-t-butoxyiminomethylcamptothecin is in free or pharmaceutically acceptable salt form, in the form of their possible enantiomers, diastereoisomers and relative mixtures, polymorphs, amorphous, partially amorphous forms, solvates, their active metabolites and prodrugs any combination thereof.

3. The composition of claim 1, wherein the composition shows at least a 1.5-fold better bioavailability when compared with 7-t-butoxyiminomethylcamptothecin in free form.

4. The composition of claim 1, wherein the effective average particle size of the nanoparticulate particles is selected from the group consisting of less than about 3,000 nm, less than about 2,000 nm, less than about 1,000 nm, less than about 500 nm.

5. The composition of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients, surface stabilizers or a combination thereof.

6. The composition of claim 1, wherein 7-t-butoxyiminomethylcamptothecin is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the 7-t-butoxyiminomethylcamptothecin and at least one surface stabilizer, not including other excipients.

7. The composition of claim 1, wherein the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 95%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of 7-t-butoxyiminomethylcamptothecin and at least one surface stabilizer, not including other excipients.

8. The composition of claim 1, wherein the at least one surface stabilizer is selected from hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, random copolymers of vinyl pyrrolidone and vinyl acetate, sodium lauryl sulfate, dioctylsulfosuccinate, poloxamers, gelatin, casein, lecithin, dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters;

polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellu lose calcium, carboxymethylcellu lose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde;

poloxamines;

Tetronic 15080, alkyl aryl polyether sulfonate;

a mixture of sucrose stearate and sucrose distearate;

p-isononylphenoxypoly-(glycidol), C₁₈H₃₇CH₂(CON(CH₃)—

CH₂(CHOH)₄(CH₂OH)₂;

decanoyl-N-methylglucamide;

n-decyl-β

-D-glucopyranoside;

n-decyl-3-D-maltopyranoside;

n-dodecyl-β

-D-glucopyranoside;

n-dodecyl-β

-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-β

-D-glucopyranoside;

n-heptyl-β

-D-thioglucoside;

n-hexyl-β

-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl-β

-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-β

-D-glucopyranoside;

octyl-β

-D-thioglucopyranoside;

PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate.

9. The composition of claim 1, wherein the composition is in a liquid oral dosage form.

10. The composition of claim 1, wherein the composition is in a solid oral dosage form.

11. The method of claim 1, wherein the formulation is in a parenteral dosage form.

12. A method of making a nanoparticulate composition comprising contacting 7-t-butoxyiminomethylcamptothecin with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate composition having an effective average particle size of less than about 4,000 nm.

13. The method of claim 12, wherein said contacting comprising grinding.

14. The method of claim 13, wherein said grinding comprising wet grinding.

15. The method of claim 12, wherein said contacting comprises homogenizing.

16. The method of claim 12, wherein said contacting comprises precipitation.

17. The method of claim 12, wherein the effective average particle size of the nanoparticulate particles is selected from the group consisting of less than about 3,000 nm, less than about 2,000 nm, less than about 1,000 nm, less than about 500 nm.

18. The method of claim 12, wherein the at least one surface stabilizer is selected from hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, random copolymers of vinyl pyrrolidone and vinyl acetate, sodium lauryl sulfate, dioctylsulfosuccinate, poloxamers, gelatin, casein, lecithin, dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters;

polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellu lose calcium, carboxymethylcellu lose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde;

poloxamines;

Tetronic 15080, alkyl aryl polyether sulfonate;

a mixture of sucrose stearate and sucrose distearate;

p-isononylphenoxypoly-(glycidol), C₁₈H₃₇CH₂(CON(CH₃)—

CH₂(CHOH)₄(CH₂OH)₂;

decanoyl-N-methylglucamide;

n-decyl-β

-D-glucopyranoside;

n-decyl-β

-D-maltopyranoside;

n-dodecyl-β

-D-glucopyranoside;

n-dodecyl-β

-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-β

-D-glucopyranoside;

n-heptyl-β

-D-thioglucoside;

n-hexyl-β

-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl-β

-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-β

-D-glucopyranoside;

octyl-β

-D-thioglucopyranoside;

PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate.

19. A method of treating a proliferative disease comprising administrating to a patient in need thereof a formulation comprising nanoparticles of 7-t-butoxyiminomethylcamptothecin and at least one surface stabilizer, wherein the nanoparticles have an effective average particle size of less than about 4,000 nm.

20. The method of claim 19, wherein the proliferative disease is breast cancer, lung cancer, gastrointestinal cancer, including esophageal, gastric, small bowel, large bowel and rectal cancer, glioma, sarcoma such as those involving bone, cartilage, soft tissue, muscle, blood and lymph vessels, ovarian cancer, myeloma, female cervical cancer, endometrial cancer, head and neck cancer, mesothelioma, renal cancer, ureter, bladder and urethral cancers, prostate cancer, skin cancers and melanoma. In particular, the inventive compositions are particularly useful for treating:

(i) a breast tumor;

a lung tumor, e.g., non-small cell lung tumor;

a gastrointestinal tumor, e.g., a colorectal tumor;

or a genitourinary tumor, e.g., a prostate tumor;

(ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics;

or

(iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.

In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition, such as a leukemia, lymphoma and multiple myeloma.

21. The method of claim 19, wherein 7-t-butoxyiminomethylcamptothecin is present in an amount selected from the group consisting of from about 99.5% to about 0.001%, from about 95% to about 0.1%, and from about 90% to about 0.5%, by weight, based on the total combined weight of the camptothecin derivative and at least one surface stabilizer, not including other excipients.

22. The method of claim 19, wherein the at least one surface stabilizer is present in an amount selected from the group consisting of from about 0.5% to about 99.999%, from about 5.0% to about 95%, and from about 10% to about 99.5%, by weight, based on the total combined dry weight of 7-t-butoxyiminomethylcamptothecin and at least one surface stabilizer, not including other excipients.

23. The method of claim 19, wherein the at least one surface stabilizer is selected from hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, random copolymers of vinyl pyrrolidone and vinyl acetate, sodium lauryl sulfate, dioctylsulfosuccinate, poloxamers, gelatin, casein, lecithin, dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters;

polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellu lose calcium, carboxymethylcellu lose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde;

poloxamines;

Tetronic 15080, alkyl aryl polyether sulfonate;

a mixture of sucrose stearate and sucrose distearate;

p-isononylphenoxypoly-(glycidol), C₁₈H₃₇CH₂(CON(CH₃)—

CH₂(CHOH)₄(CH₂OH)₂;

decanoyl-N-methylglucamide;

n-decyl-β

-D-glucopyranoside;

n-decyl-β

-D-maltopyranoside;

n-dodecyl-β

-D-glucopyranoside;

n-dodecyl-β

-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-β

-D-glucopyranoside;

n-heptyl-β

-D-thioglucoside;

n-hexyl-β

-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl-β

-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-β

-D-glucopyranoside;

octyl-β

-D-thioglucopyranoside;

PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate.

24. The method of claim 19, wherein the formulation is in a liquid oral dosage form.

25. The method of claim 19, wherein the formulation is in a solid oral dosage form.

26. The method of claim 19, wherein the formulation is in a parenteral dosage form.

27. A dosage form comprising 0.001-100 mg by weight of 7-t-butoxyiminomethylcamptothecin.

28. The dosage form of claim 27, comprising 0.01-25 mg by weight of 7-t-butoxyiminomethylcamptothecin.

29. The dosage form of claim 27, comprising 0.05-10 mg by weight of 7-t-butoxyiminomethylcamptothecin.